MPLA Synthetic VacciGrade™
|MPLAs Vaccigrade™||Unit size||Cat. code||Docs||Qty||Price|
Synthetic monophosphoryl lipid A - TLR4 agonist
You may also need : EndoFit Ovalbumin | View more associated products ▼
Synthetic lipid A
Synthetic lipid A from E. coli, serotype R515 (MPLAs) is a pure monophosphoryl lipid A compound produced by chemical synthesis.
MPLAs activates TLR4 but does not activate TLR2 reflecting its high purity. MPLAs contains 6 fatty acyl groups, while MPLA purified from bacteria contains a mixture of 5, 6, and 7 acyl lipid A.
MPLA has been tested as an adjuvant in mice and reported to induce a strong Th1 response.
MPLA Synthetic VacciGrade™ is a high-quality pre-clinical grade.
MPLA Synthetic VacciGrade™ is for research use only, and not for human or veterinary use.
Back to the top
Description: TLR4 agonist VacciGrade™
Polarization of adaptive immune response: Th1 response
CAS Number: 1246298-63-4
Working concentration: 2- 20 μg/mouse
Molecular weight: 1763.47 g/mol
Solubility: 1 mg/ml in DMSO
- Sterility guaranteed
- The presence of other bacterial components is controlled using HEK-Blue™ TLR2 cells
- Endotoxin level is measured using a chromogenic LAL assay
MPLAs VacciGrade™ is provided as a clear, lipidic film.
- 1 mg MPLAs VacciGrade™
- 10 ml sterile endotoxin-free physiological water (NaCl 0.9%)
MPLAs VacciGrade™ is shipped at room temperature.
Store at -20˚C.
Product is stable 1 year when properly stored.
Upon resuspension, prepare aliquots of MPLAs VacciGrade™ and store at -20˚C.
Resuspended product is stable 6 months when properly stored.
Avoid repeated freeze-thaw cycles.Back to the top
VacciGrade™ is a high-quality pre-clinical grade. VacciGrade™ products are filter-sterilized (0.2 µm) and filled under strict aseptic conditions in a clean room*. The absence of bacterial contamination is assessed by a sterility test using a pharmacopeia-derived assay. The level of bacterial contaminants (endotoxins and lipoproteins) in each lot is verified using a LAL assay and/or a TLR2 and TLR4 reporter assay.
*Except for LPS VacciGrade™, which is prepared in a laminar flow hood dedicated to LPS.
MPLA is a low-toxicity derivative of lipopolysaccharide (LPS), that retains the immunologically active lipid A portion of the parent molecule . While the toxicity associated with LPS prohibits its potential clinical use, MPLA is being developed as a vaccine adjuvant . Both LPS and MPLA are TLR4 agonists, but they signal through different adaptors, MyD88 and TRIF, respectively. The reduced toxicity of MPLA is attributed to the preferential recruitment of TRIF upon TLR4 activation, resulting in decreased induction of inflammatory cytokines .
MPLA has been tested as an adjuvant in mice and reported to induce a strong Th1 response [4-5]. Although the mechanism of action of MPLA has not been fully eludicated, it has been suggested that MPLA improves vaccine immunogenicity by enhancing antigen presenting cell maturation .
1. Okemoto K. et al., 2006. A potent adjuvant monophosphoryl lipid A triggers various immune responses, but not secretion of IL-1beta or activation of caspase-1. J Immunol. 176(2):1203-8.
2. Casella CR. et al., 2008. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci. 65(20):3231-40.
3. Mata-Haro V. et al., 2007. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science. 316(5831):1628-32.
4. Fransen F. et al., 2007. Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup. Infect Immun. 75(12) :5939-46.
5. Rhee EG. et al., 2010. TLR4 Ligands Augment Antigen-Specific CD8+ T Lymphocyte Responses Elicited by a Viral Vaccine Vector. J. Virol. 84: 10413 - 10419.
6. Didierlaurent A. et al., 2009. AS04, an aluminum salt- and TLR4 agonistbased adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 183(10): 6186-97.